Isosorbide-2-benzyl carbamate-5-salicylate, a peripheral anionic site binding subnanomolar selective butyrylcholinesterase inhibitor

Ciaran G. Carolan, Gerald P. Dillon, Denise Khan, Sheila A. Ryder, Joanne M. Gaynor, Sean Reidy, Juan F. Marquez, Mike Jones, Valerie Holland, John F. Gilmer

Research output: Contribution to journalArticlepeer-review

60 Citations (Scopus)

Abstract

Isosorbide-2-benzyl carbamate-5-benzoate is a highly potent and selective BuChE inhibitor. Meanwhile, isosorbide-2-aspirinate-5-salicylate is a highly effective aspirin prodrug that relies on the salicylate portion to interact productively with human BuChE. By integrating the salicylate group into the carbamate design, we have produced isosorbide-2-benzyl carbamate-5-salicylate, an inhibitor of high potency (150 pM) and selectivity for human BuChE over AChE (666000) and CES2 (23000). Modeling and mutant studies indicate that it achieves its exceptional potency because of an interaction with the polar D70/Y332 cluster in the PAS of BuChE in addition to pseudosubstrate interactions with the active site.

Original languageEnglish
Pages (from-to)1190-1199
Number of pages10
JournalJournal of Medicinal Chemistry
Volume53
Issue number3
DOIs
Publication statusPublished - 2010

Fingerprint

Dive into the research topics of 'Isosorbide-2-benzyl carbamate-5-salicylate, a peripheral anionic site binding subnanomolar selective butyrylcholinesterase inhibitor'. Together they form a unique fingerprint.

Cite this